Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 555 Long Wharf Dr NEW HAVEN CT 06511-6107 |
Tel: | 1-475-3558462 |
Website: | https://www.bioxceltherapeutics.com |
IR: | See website |
Key People | ||
Vimal Mehta President, Chief Executive Officer, Director | Richard I. Steinhart Chief Financial Officer, Senior Vice President | Frank D. Yocca Executive Vice President, Chief Scientific Officer |
Vincent J. O'Neill Executive Vice President, Chief of Product Development and Medical Officer | Javier Rodriguez Senior Vice President, Chief Legal Officer, Corporate Secretary |
Business Overview |
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company's most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. |
Financial Overview |
For the nine months ended 30 September 2024, BioXcel Therapeutics Inc revenues increased 89% to $1.9M. Net loss decreased 69% to $48.7M. Revenues reflect PHARMACEUTICAL PREPARATIONS segment increase from $798K to $1.9M. Lower net loss reflects PHARMACEUTICAL PREPARATIONS segment loss decrease of 44% to $56.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$5.40 to -$1.40. |
Employees: | 74 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $78.89M as of Sep 30, 2024 |
Annual revenue (TTM): | $2.28M as of Sep 30, 2024 |
EBITDA (TTM): | -$73.91M as of Sep 30, 2024 |
Net annual income (TTM): | -$71.00M as of Sep 30, 2024 |
Free cash flow (TTM): | -$84.08M as of Sep 30, 2024 |
Net Debt Last Fiscal Year: | $64.05M as of Sep 30, 2024 |
Shares outstanding: | 49,628,948 as of Dec 17, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |